Bi-functional Polypeptides for Intracellular Tau Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for tauopathies, such as Alzheimer's disease, face challenges due to the limited penetration of full-length antibodies into brain cells where tau protein aggregates reside, hindering effective reduction of tau misfolding and aggregation.
Innovation Solution
Development of bi-functional polypeptides comprising an antigen binding domain that specifically binds to tau and a proteasome-targeting PEST motif, enhancing the degradation of tau by facilitating its targeting to the proteasome for degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If full-length antibodies are used to bind tau, then tau binding affinity is improved, but penetration into brain cells deteriorates
Solution Approach 1:
The patent segments the full-length antibody into smaller functional fragments, specifically single-chain Fv (scFv) fragments, that retain tau binding capability while reducing size to enable cellular penetration. This segmentation allows the therapeutic agent to maintain affinity for tau while gaining access to intracellular compartments where tau aggregates reside.
Solution Approach 2:
The invention extracts only the essential antigen-binding domain (Fv fragment) from the full-length antibody, discarding the Fc region and other non-essential portions. This extraction creates a minimized molecular entity that preserves tau recognition while eliminating size constraints that hinder cellular entry.
2Reliability
If immunotherapy is used to reduce tau levels, then tau misfolding reduction is improved, but device complexity increases
Solution Approach 1:
The patent merges two distinct functions into a single polypeptide molecule: (1) tau binding via the scFv domain and (2) proteasomal degradation targeting via the PEST motif. This consolidation eliminates the need for separate therapeutic agents or complex delivery systems, simplifying the overall therapeutic mechanism while maintaining efficacy.
Solution Approach 2:
The bi-functional polypeptide serves multiple functions simultaneously: it acts as a tau-specific binder, a degradation signal carrier, and a proteasome substrate director. This multi-functionality reduces the complexity of requiring multiple separate therapeutic components while achieving comprehensive tau reduction.
3Measurement precision
If full-length antibodies are used for tau binding, then binding specificity is improved, but manufacturing complexity increases
Solution Approach 1:
Segmenting the antibody into scFv fragments simplifies the manufacturing process by reducing the number of amino acid residues that need to be synthesized and folded correctly. The smaller size facilitates easier production in recombinant expression systems while maintaining the critical complementarity determining regions (CDRs) that provide binding specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bi-functional polypeptides effectively bind to tau and promote its degradation within cells, potentially inhibiting the formation of neurofibrillary tangles and slowing down tauopathy progression.
Implementation Method 1
a second domain comprising a proteasome-targeting PEST motif
Data Source
AI summary
Disclosed herein are multifunctional polypeptides comprising a first domain comprising an anti-tau antigen binding domain and a second domain comprising a proteasome-targeting PEST motif, and methods for using these polypeptides in treatment of tauopathies.